Akinboro O et al. Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score ≥50%: FDA pooled analysis. ASCO 2022;Abstract 9000.
Carrizosa DR et al. CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions. ASCO 2022;Abstract 3006.
Cho BC et al. Durvalumab (d) ± tremelimumab (t) + chemotherapy (ct) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON. ASCO 2022;Abstract 9035.
Janne PA et al. Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC. ASCO 2022;Abstract TPS3161.
Krebs MG et al. Amivantamab in NSCLC patients with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. ASCO 2022;Abstract 9008.
Levy BP et al. Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naïve advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 ≥ 50% and without actionable genomic alterations. ASCO 2022;Abstract TPS3162.
Li BT et al. Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). ASCO 2022;Abstract TPS9137.
Lin SH et al. Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1 high locally advanced non-small cell lung cancer. ASCO 2022;Abstract 8513.
Mok TSK et al. Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non-small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study. ASCO 2022;Abstract 9118.
Naidoo J et al. Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC. ASCO 2022;Abstract 8541.
Nakajima EC et al. Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutation status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis. ASCO 2022;Abstract 9001.
Ou S-HI et al. Matching-adjusted indirect comparison (MAIC) of mobocertinib vs amivantamab in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins). ASCO 2022;Abstract 9115.
Özgüroğlu M et al. Adverse events self-reported by patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC) treated with durvalumab (D) + platinum-etoposide (EP) or EP in the CASPIAN study. ASCO 2022;Abstract 8571.
Passaro A et al. Overcoming therapy resistance in EGFR-mutant lung cancer. Nature Cancer 2021;2(4):377-91. Abstract
Sabari JK et al. Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial. ASCO 2022;Abstract LBA9009.
Shu CA et al. Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. ASCO 2022;Abstract 9006.
Steuer CE et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations. ASCO 2022;Abstract 9017.
Spira AI et al. KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. ASCO 2022;Abstract 9002.
Wu Y-L et al. Capmatinib plus Osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification. ASCO 2022;Abstract TPS9153.
Yu HA et al. Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations. ASCO 2022;Abstract 9007.